Switzerland-based Silony Medical International has completed the acquisition of the global fusion business of US-based Centinel Spine with the aim of entering the US spinal fusion market.
Following the , the company changed its name to 鈥楽ilony Spine鈥� to emphasise its focus on spine fusion technology. The company plans to utilise Centinel鈥檚 distribution network to propel the former鈥檚 growth in the US market.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Spinal fusion is a surgical procedure that involves joining two or more bones in the spine to form a single solid bone. This connection prevents bone movement, thereby, relieving pain.
A GlobalData market model forecasts the spinal fusion market to grow from $7.5bn in 2022 to $8.89bn by 2030. Most of the growth is expected for interbody devices which are expected to grow at a CAGR of 6.03%, from $2.7bn in 2022 to $4.1bn in 2030.
In addition to Centinel鈥檚 assets, Silony will also incorporate the US company’s personnel and update the latter’s interbody fusion platform, STALIF. The interbody fusion devices help to restore spinal balance and recreate spinal alignment and stability through surgery.
Other devices in the company’s portfolio include Verticale posterior screw and rod fusion platform, along with Roccia and Favo interbody fusion (IBF) systems.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFollowing the divestment of its fusion business, Centinel plans to focus on its total disc replacement technology platform, prodisc. The company鈥檚 prodisc catalogue generated $45m in revenue in 2022, as per .
Recent advancements in spinal fusion technology include Xenix Medical鈥檚 nanotechnology-based interbody fusion implants, receiving 510(k) clearance by the US Food and Drug Administration.
